Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
Department of Research Methodology, Measurement, and Data analysis, University of Twente, Enschede, The Netherlands.
BMJ Open Respir Res. 2021 Aug;8(1). doi: 10.1136/bmjresp-2021-000960.
The blood eosinophil count has been shown to be a promising biomarker for establishing personalised treatment strategies to reduce corticosteroid use, either inhaled or systemic, in chronic obstructive pulmonary disease (COPD). Eosinophil levels seem relatively stable over time in stable state, but little is known whether this is also true in subsequent severe acute exacerbations of COPD (AECOPD).
To determine the stability in eosinophil categorisation between two subsequent severe AECOPDs employing frequently used cut-off levels.
During two subsequent severe AECOPDs, blood eosinophil counts were determined at admission to the hospital in 237 patients in the Cohort of Mortality and Inflammation in COPD Study. The following four cut-off levels were analysed: absolute counts of eosinophils ≥0.2×10⁹/L (200 cells/µL) and ≥0.3×10⁹/L (300 cells/µL) and relative eosinophil percentage of ≥2% and ≥3% of total leucocyte count. Categorisations were considered stable if during the second AECOPD their blood eosinophil status led to the same classification: eosinophilic or not.
Depending on the used cut-off, the overall stability in eosinophil categorisation varied between 70% and 85% during two subsequent AECOPDs. From patients who were eosinophilic at the first AECOPD, 34%-45% remained eosinophilic at the subsequent AECOPD, while 9%-21% of patients being non-eosinophilic at the first AECOPD became eosinophilic at the subsequent AECOPD.
The eosinophil variability leads to category changes in subsequent AECOPDs, which limits the eosinophil categorisation stability. Therefore, measurement of eosinophils at each new exacerbation seems warranted.
血液嗜酸性粒细胞计数已被证明是一种很有前途的生物标志物,可以制定个性化的治疗策略,以减少慢性阻塞性肺疾病(COPD)患者使用吸入或全身皮质类固醇。在稳定状态下,嗜酸性粒细胞水平似乎随时间相对稳定,但对于随后的 COPD 重度急性加重(AECOPD)是否也是如此,知之甚少。
确定使用常用截断值在两次随后的重度 AECOPD 中嗜酸性粒细胞分类的稳定性。
在 COPD 死亡率和炎症队列研究中,237 名患者在两次随后的重度 AECOPD 期间,在入院时测定血液嗜酸性粒细胞计数。分析了以下四个截断值:嗜酸性粒细胞绝对计数≥0.2×10⁹/L(200 个细胞/µL)和≥0.3×10⁹/L(300 个细胞/µL)以及相对嗜酸性粒细胞百分比≥2%和≥3%的总白细胞计数。如果在第二次 AECOPD 期间,其血液嗜酸性粒细胞状态导致相同的分类:嗜酸性粒细胞或非嗜酸性粒细胞,则认为分类稳定。
根据所用截断值的不同,两次随后的 AECOPD 期间,嗜酸性粒细胞分类的总体稳定性在 70%至 85%之间。在第一次 AECOPD 时为嗜酸性粒细胞的患者中,有 34%-45%在随后的 AECOPD 中仍为嗜酸性粒细胞,而在第一次 AECOPD 时非嗜酸性粒细胞的患者中有 9%-21%在随后的 AECOPD 中变为嗜酸性粒细胞。
嗜酸性粒细胞的变化导致随后的 AECOPD 中类别发生变化,从而限制了嗜酸性粒细胞分类的稳定性。因此,似乎需要在每次新的加重时测量嗜酸性粒细胞。